Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma - Takeaways - MDSpire

Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma

  • By

  • Yongliang Niu

  • Junguo Li

  • Bowen Ding

  • Haitang Yang

  • Hui Zhao

  • Diming Wang

  • July 7, 2026

  • 0 min

Share

  • 1

    The study analyzed 137 patients with stage IIIA–IIIB lung squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy.

  • 2

    A major pathological response (MPR) and pathological complete response (pCR) rate of 56.2% was achieved among the patients.

  • 3

    Ki-67 expression at an optimal cutoff of 55% was identified as a significant predictor of MPR/pCR in the study.

  • 4

    High Ki-67 (≥55%) correlated with a higher MPR/pCR rate compared to low Ki-67 (69.6% vs. 27.9%, P<0.001).

  • 5

    Smoking status was also found to be an independent predictor of MPR/pCR alongside Ki-67 expression.

Original Source(s)

Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma

  • by Yongliang Niu, Junguo Li, Bowen Ding, Haitang Yang, Hui Zhao, Diming Wang

  • July 7, 2026

Related Content

The prognostic impact of squamous differentiation in bladder cancer after radical cystectomy: a propensity score-matched comparative analysis of pure urothelial carcinoma, urothelial carcinoma with squamous differentiation, and squamous cell carcinoma

Prostate Cancer Screening—Where We’ve Been, Where We Are, and What Comes Next

Case Report: Pediatric Philadelphia chromosome-positive T-lymphoblastic leukemia relapsing as chronic-phase CML after treatment discontinuation